Laboratory

Global Calibration Services Market Strategies and Trends Report 2023: Focus on Aerospace & Defence, Agro & Biomedical, Electronic & Communications, and Industry & Manufacturing - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

7.1.11 New Chairman of the Board at Transcat, Inc.

Key Points: 

7.1.11 New Chairman of the Board at Transcat, Inc.
7.1.15 Transcat Acquires TTE Laboratories, Inc.
7.1.19 Transcat acquires Infinite Integral Solutions Inc.
7.1.26 Transcat Acquires Angel's Instrumentation Inc.

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

Retrieved on: 
Thursday, January 12, 2023

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.
  • Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications.
  • His research has been conducted in models of Alzheimer’s disease, age-related hearing loss and other conditions resulting from age-related decline.
  • “Dr.

New Company, Velsera, Represents Summa Equity's Vision to Improve Global Health Outcomes

Retrieved on: 
Thursday, January 12, 2023

The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).

Key Points: 
  • The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
  • The promise of precision medicine is held back by barriers across routine health practice and discovery.
  • Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world.
  • Velsera unites these companies to advance and bring together their missions which are centered around improving health globally through multi-omics and insights.

Global Toxicity Testing Outsourcing Market Report to 2028: Increased Efficiency in Drug Discovery and Personalized Therapy Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The "Global Toxicity Testing Outsourcing Market Size, Share & Industry Trends Analysis Report by End-use, Method, GLP, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Toxicity Testing Outsourcing Market Size, Share & Industry Trends Analysis Report by End-use, Method, GLP, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Toxicity Testing Outsourcing Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 8.4% CAGR during the forecast period.
  • The pharmaceutical business, biotechnology firms, contract research groups, or environmental scientists may all carry out toxicology testing.
  • Therefore, COVID-19 propelled the trend of outsourcing and as such had a positive impact on the toxicity testing outsourcing market.

Eurofins CDMO Alphora Inc. (Canada) Announces the Relocation and Expansion of its Analytical Services and Research & Development Laboratories to New Campus Hosting all Biopharmaceutical Activities

Retrieved on: 
Wednesday, January 11, 2023

Eurofins CDMO Alphora Inc. is pleased to announce the relocation and expansion of its API development laboratories from 2395 Speakman Drive to its new, owned facility at 2070 Hadwen Road, located within the Sheridan Research Park in Mississauga, Ontario, Canada.

Key Points: 
  • Eurofins CDMO Alphora Inc. is pleased to announce the relocation and expansion of its API development laboratories from 2395 Speakman Drive to its new, owned facility at 2070 Hadwen Road, located within the Sheridan Research Park in Mississauga, Ontario, Canada.
  • View the full release here: https://www.businesswire.com/news/home/20230111005622/en/
    This 56,000 square foot building is the new home of Eurofins CDMO Alphora Inc’s API process R&D activity, solid-state R&D activity and its analytical services team.
  • The campus is also within 2.5 km of Eurofins CDMO Alphora Inc.’s existing API production facility.
  • This latest addition is another important step towards Eurofins CDMO Alphora Inc’s’ vision to build out its Sheridan Research Park campus with additional capacity and technologies in CDMO and biopharmaceutical services.

Paige Collaborates with Microsoft to Transform Cancer Diagnosis and Treatment with the Use of Pathology AI

Retrieved on: 
Wednesday, January 11, 2023

Microsoft will also make a strategic investment in Paige to accelerate the development and deployment of life-saving AI diagnostics.

Key Points: 
  • Microsoft will also make a strategic investment in Paige to accelerate the development and deployment of life-saving AI diagnostics.
  • Through the collaboration, Paige and Microsoft will scale Paige’s technology globally and accelerate the adoption of AI in digital pathology.
  • Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, is currently the only company to have received FDA approval for an AI algorithm in pathology.
  • Paige becoming a Microsoft Cloud for Healthcare partner extends the solution’s robust capabilities and helps Paige reach new customers.

Antitrust Violation vs. Injury-in-Fact: A distinction that makes a difference

Retrieved on: 
Saturday, February 4, 2023

But private plaintiffs must make an additional showing: to establish antitrust ‘standing,’ private plaintiffs must prove that the antitrust violation caused harm to them.

Key Points: 
  • But private plaintiffs must make an additional showing: to establish antitrust ‘standing,’ private plaintiffs must prove that the antitrust violation caused harm to them.
  • This distinction is deeply rooted in our system of antitrust enforcement, which permits many types of enforcers but limits standing to those with a cognizable claim of injury.
  • But when courts and litigants miss this doctrinal distinction on the road to resolving a case, it can have significant implications for antitrust law and policy.
  • The brief takes no position on the merits of the case, but instead explains that the district court missed the important distinction between an antitrust violation and an injury-in-fact.

The Worldwide HPV Testing and Pap Test Industry is Projected to Reach $9.2 Billion by 2027: Rising HPV Cases and Subsequent Increase in Cervical Cancer Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period
    The HPV testing and Pap test market is segmented into HPV testing and Pap test.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.
  • The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period
    The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening.

Global and Regional Molecular Oncology Diagnostics Market Report 2022: Analysis and Forecasts, 2021-2032 - Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.

Key Points: 
  • The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.
  • The rising global cancer incidence and the growing demand for early detection are expected to drive the growth of the global molecular oncology diagnostics market during the forecast period.
  • The presence of major kit and assay providers of molecular oncology diagnostics has a major impact on the market.
  • Based on products, the global molecular oncology diagnostics market is expected to be dominated by kit and assay.

Vizgen Appoints Paul Rasmussen to Spearhead Recent Expansion of MERSCOPE™ in APAC Region

Retrieved on: 
Tuesday, January 10, 2023

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the appointment of industry veteran Paul Rasmussen as Regional Vice President, Asia Pacific and Japan.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the appointment of industry veteran Paul Rasmussen as Regional Vice President, Asia Pacific and Japan.
  • View the full release here: https://www.businesswire.com/news/home/20230110005036/en/
    “With the addition of Paul to our global team, Vizgen is well positioned to meet the growing demand for our market-leading MERSCOPE™ spatial genomics platform and open access datasets,” said Terry Lo, President and CEO of Vizgen.
  • He most recently served as Director of APAC Life Sciences Operations.
  • "This is a tremendously exciting time of growth for Vizgen, and I am thrilled for the opportunity to play a key role in leading their continued global expansion,” said Mr. Rasmussen.